TY - JOUR
T1 - Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease
T2 - A 90-day multi-center study
AU - Tashkin, Donald P.
AU - Ashutosh, Kumar
AU - Bleecker, Eugene R.
AU - Britt, E. James
AU - Cugell, David W.
AU - Cummiskey, Joseph M.
AU - Delorenzo, Lawrence
AU - Gilman, Murray J.
AU - Gross, Gary N.
AU - Gross, Nicholas J.
AU - Kotch, Arthur
AU - Lakshminarayan, Sambasiva
AU - Maguire, George
AU - Miller, Matthew
AU - Plummer, Alan
AU - Renzetti, Attilio
AU - Sackner, Marvin A.
AU - Skoroqin, Morton S.
AU - Wanner, Adam
AU - Watanabe, Suetaro
PY - 1986/11/14
Y1 - 1986/11/14
N2 - The short- and long-term efficacy and safety of an inhaled quaternary ammonium anticholinergic agent, ipratropium bromide, and a beta agonist aerosol, metaproterenol, were compared in 261 non-atopic patients with chronic obstructive pulmonary disease (COPD). The study was a randomized, double-blind, 90-day, parallel-group trial. On three test days-one, 45, and 90-mean peak responses for forced expiratory volume in one second and forced vital capacity and mean area under the time-response curve were higher for ipratropium than for metaproterenol. Clinical improvement was noted in both treatment groups, especially during the first treatment month, with persistence of improvement throughout the remainder of the study. Side effects were relatively infrequent and generally mild; tremor, a complication of beta agonists, was not reported by any subject receiving ipratropium. These results support the effectiveness and safety of long-term treatment with inhaled ipratropium in COPD.
AB - The short- and long-term efficacy and safety of an inhaled quaternary ammonium anticholinergic agent, ipratropium bromide, and a beta agonist aerosol, metaproterenol, were compared in 261 non-atopic patients with chronic obstructive pulmonary disease (COPD). The study was a randomized, double-blind, 90-day, parallel-group trial. On three test days-one, 45, and 90-mean peak responses for forced expiratory volume in one second and forced vital capacity and mean area under the time-response curve were higher for ipratropium than for metaproterenol. Clinical improvement was noted in both treatment groups, especially during the first treatment month, with persistence of improvement throughout the remainder of the study. Side effects were relatively infrequent and generally mild; tremor, a complication of beta agonists, was not reported by any subject receiving ipratropium. These results support the effectiveness and safety of long-term treatment with inhaled ipratropium in COPD.
UR - http://www.scopus.com/inward/record.url?scp=0023048731&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023048731&partnerID=8YFLogxK
U2 - 10.1016/0002-9343(86)90468-7
DO - 10.1016/0002-9343(86)90468-7
M3 - Article
C2 - 2947465
AN - SCOPUS:0023048731
SN - 0002-9343
VL - 81
SP - 81
EP - 90
JO - The American journal of medicine
JF - The American journal of medicine
IS - 5 SUPPL. 1
ER -